BioGaia AB (publ) Total Liabilities
BioGaia AB (publ) total liabilities. Based on the latest financial reports, BioGaia AB (publ) (BIOG-B) has total liabilities worth Skr235.14 Million SEK (≈ $25.30 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of BioGaia AB (publ) to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BioGaia AB (publ) (2002–2025)
Total liabilities of BioGaia AB (publ) from 2002 to 2025. This chart illustrates how BioGaia AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of BioGaia AB (publ) to see how much of total assets are deployed in long-term investments.
BioGaia AB (publ) Competitors by Total Liabilities
The table below lists competitors of BioGaia AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Eazytec Co Ltd
SHG:688258
|
China | CN¥697.80 Million |
|
Sylvamo Corp
NYSE:SLVM
|
USA | $1.85 Billion |
|
Shenzhen Noposion Agrochemicals Co Ltd
SHE:002215
|
China | CN¥7.29 Billion |
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
China | CN¥4.24 Billion |
|
Hanall Biopharma
KO:009420
|
Korea | ₩44.17 Billion |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS
|
India | Rs21.16 Billion |
|
FLEX LNG Ltd
F:0QQA
|
Germany | €1.94 Billion |
|
Preferred Bank
NASDAQ:PFBC
|
USA | $6.94 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down BioGaia AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BioGaia AB (publ) asset portfolio.
Liquidity & Leverage Metrics
BioGaia AB (publ) Total Liabilities Ratios Explained
BioGaia AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioGaia AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioGaia AB (publ) (2002–2025)
The table below shows the annual total liabilities of BioGaia AB (publ) from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr283.59 Million ≈ $30.52 Million |
-8.54% |
| 2024-12-31 | Skr310.07 Million ≈ $33.37 Million |
+1.48% |
| 2023-12-31 | Skr305.54 Million ≈ $32.88 Million |
+26.49% |
| 2022-12-31 | Skr241.55 Million ≈ $25.99 Million |
-3.65% |
| 2021-12-31 | Skr250.69 Million ≈ $26.98 Million |
+50.08% |
| 2020-12-31 | Skr167.04 Million ≈ $17.98 Million |
+5.70% |
| 2019-12-31 | Skr158.03 Million ≈ $17.01 Million |
+4.07% |
| 2018-12-31 | Skr151.85 Million ≈ $16.34 Million |
+35.31% |
| 2017-12-31 | Skr112.22 Million ≈ $12.08 Million |
+52.07% |
| 2016-12-31 | Skr73.80 Million ≈ $7.94 Million |
-4.59% |
| 2015-12-31 | Skr77.34 Million ≈ $8.32 Million |
+8.91% |
| 2014-12-31 | Skr71.02 Million ≈ $7.64 Million |
+6.69% |
| 2013-12-31 | Skr66.56 Million ≈ $7.16 Million |
+10.52% |
| 2012-12-31 | Skr60.23 Million ≈ $6.48 Million |
+21.73% |
| 2011-12-31 | Skr49.48 Million ≈ $5.32 Million |
+22.17% |
| 2010-12-31 | Skr40.50 Million ≈ $4.36 Million |
+116.62% |
| 2009-12-31 | Skr18.70 Million ≈ $2.01 Million |
-14.58% |
| 2008-12-31 | Skr21.89 Million ≈ $2.36 Million |
+37.97% |
| 2007-12-31 | Skr15.86 Million ≈ $1.71 Million |
-2.28% |
| 2006-12-31 | Skr16.23 Million ≈ $1.75 Million |
+5.59% |
| 2005-12-31 | Skr15.37 Million ≈ $1.65 Million |
-9.60% |
| 2004-12-31 | Skr17.01 Million ≈ $1.83 Million |
-19.23% |
| 2003-12-31 | Skr21.05 Million ≈ $2.27 Million |
-37.41% |
| 2002-12-31 | Skr33.64 Million ≈ $3.62 Million |
-- |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more